Comparison of carrier and allele frequencies of HLA subtypes between CM-induced patients with SJS/TEN developing SOCs and normal controls
| HLA-A | Carrier frequency | Allele frequency | ||||||||
| Case | Control | P value | OR (95% CI) | Case | Control | P value | OR (95% Cl) | |||
| Fisher | Bonferroni correction | Fisher | Bonferroni correction | |||||||
| A*02:06 | 7.7% (1/13) | 5.1% (5/98) | 0.535 | 3.8% (1/26) | 3.1% (6/196) | 0.587 | ||||
| A*02:07 | 38.5% (5/13) | 10.2% (10/98) | 0.016 | 0.155 | 5.56 (1.52 to 20.00) | 26.9% (7/26) | 5.1% (10/196) | 0.001 | 0.012 | 6.67 (2.33 to 20.00) |
| A*11:01 | 30.8% (4/13) | 55.1% (54/98) | 0.140 | 23.1% (6/26) | 31.6% (62/196) | 0.498 | ||||
| B*46:01 | 30.77% (6/13) | 19.4% (19/98) | 0.070 | 30.8% (8/26) | 10.2% (20/196) | 0.008 | 0.076 | 3.85 (1.52 to 10.00) | ||
Bold type denotes p values with significance.
CM, cold medicine; HLA, human leucocyte antigen; SJS, Stevens-Johnson syndrome; SOCs, severe ocular complications; TEN, toxic epidermal necrolysis.